Navigation Links
Cellectis bioresearch Makes Genome Engineering Affordable for All Users
Date:2/28/2011

PARIS, Feb. 28, 2011 /PRNewswire/ -- Cellectis bioresearch, a specialist in genome customization and subsidiary of Cellectis (Alternext: ALCLS), has today launched TALEN Access™, the first fee-for-service custom TALEN(1).

Recognized as a pioneer in the development of innovative research products for genome customization, Cellectis bioresearch brings today the life sciences community a new tool for specifically modifying genes in any type of cell.

The service will start with the TALEN Access™ offer, which provides a pair of TALENs for 5,000 euro/US$, delivered in less than 3 weeks.

"What we are offering here is a true commercial revolution," said Luc Selig, VP Sales and Marketing at Cellectis bioresearch. "We are keeping our promise to make genome customization affordable for the hundred of thousands academic research labs."

For further information or to place orders, please go to www.cellectis-bioresearch.com/talen.

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on sequence specific nucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies.

The kits can be purchased online from www.cellectis-bioresearch.com. More information on the website.

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

More information at www.cellectis.com.


'/>"/>
SOURCE Cellectis bioresearch
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cellectis In-Licenses Induced Pluripotent Stem Cell Technology From iPS Academia Japan
2. Cellectis Publishes Its Financial Statement for the First Half of 2010
3. Cellectis bioresearch Announces Establishment of Subsidiary in the US
4. Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India
5. Cellectis Bioresearch and Cedarlane Join Forces for the Distribution of cGPS® and cGPS® Custom Kits in Canada
6. New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearchs cGPS® CHO-K1 Kit to be Highly Efficient for Drug Discovery
7. SAP Makes Life Easier for Patients and More Efficient for Healthcare Providers Through New Technology
8. Pinnaclife Makes it Official With Launch Slated for March 1st
9. Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
10. US FDA Advisory Committee Makes Recommendation on New Drug Application for Vandetanib in Advanced Medullary Thyroid Cancer
11. Panasonic Makes Investment in Houston-based CardioNexus Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:7/9/2014)... signals active in almost all types of cancer sends ... may help fuel a tumour,s uncontrolled growth, new research ... London, identified a molecular trigger responsible for ratcheting up ... factory that makes the building blocks cancer cells need ... signalling pathway, called SREBP, controls the flow of messages ...
(Date:7/9/2014)... PROVIDENCE, R.I. Researchers have found that fecal ... difficile in immunocompromised patients. This is the result ... gastroenterologist in the Center for Women,s Gastrointestinal Medicine at ... have been published online in advance of print in ... Clostridium difficile , or C. diff , has ...
(Date:7/9/2014)... There has been a sharp increase in the ... using MyChart, the online, interactive service that allows patients ... healthcare providers, schedule appointments, and renew prescriptions. , Over ... MyChart each year increased five-fold, while the ... 10-fold, according to a study by Dr. David ...
(Date:7/9/2014)... Institute of Allergy and Infectious Diseases (NIAID), part ... an early-stage clinical trial of CRS3123, an investigational ... ( C. difficile ) infection. CRS3123 (previously ... inhibits C. difficile growth while sparing normal intestinal ... up to 30 healthy men and women ages ...
(Date:7/9/2014)... , , , , , ... , , , , ... assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , ... , , , , , ... , , , , , , ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ), a ... products, is scheduled,to announce its financial results for ... 2008, before the market opens. At 9:00 a.m. ... conference call to review the,Company,s third quarter financial ...
... The American Fertility Association,introduces Manicures and Martinis, ... women together in a casual setting over manicures ... preserving fertility. It,s,free, relaxing, fun, and educational. The ... hosted by leading professionals in the reproductive medical,field, ...
... TUCSON, Ariz., Oct. 30 NaturalNews.com, the ... one million health-conscious,consumers, has posted audio interviews ... of "Home Safe Home," and Byron Richards, ... nutritional supplement,provider. Both interviews are available as ...
... One of the Top 10 Most Interesting Metabolic ... 30 Genaera,Corporation (NASDAQ: GENR ) will ... held November 3-5 at the Lowes Hotel in,Philadelphia, ... Scientific Officer, will provide an overview on MSI-1436 ...
... are adjusted , , WEDNESDAY, Oct. 29 (HealthDay News) -- The ... it may pose problems more serious than adjusting sleep patterns. ... of heart attacks following the semi-annual one-hour time changes, although ... very first study on this topic and further studies are ...
... - Nuvo Research Inc.,(TSX: NRI), a Canadian drug development ... that are delivered to and through the skin,using its ... and operational results for the three and nine,months ended ... - The Company remains on target to ...
Cached Medicine News:Health News:MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results 2Health News:The American Fertility Association Announces Plan to Help Young Women Preserve Fertility 2Health News:NaturalNews Posts Audio Interview with Consumer Chemical Expert Debra Lynn Dadd on Bisphenol-A 2Health News:Genaera to Present at Therapeutic Area Partnerships 2008 2Health News:Semi-Annual Time Changes May Affect the Heart 2Health News:Semi-Annual Time Changes May Affect the Heart 3Health News:NUVO announces third quarter 2008 financial results 2Health News:NUVO announces third quarter 2008 financial results 3Health News:NUVO announces third quarter 2008 financial results 4Health News:NUVO announces third quarter 2008 financial results 5Health News:NUVO announces third quarter 2008 financial results 6Health News:NUVO announces third quarter 2008 financial results 7Health News:NUVO announces third quarter 2008 financial results 8Health News:NUVO announces third quarter 2008 financial results 9Health News:NUVO announces third quarter 2008 financial results 10Health News:NUVO announces third quarter 2008 financial results 11Health News:NUVO announces third quarter 2008 financial results 12Health News:NUVO announces third quarter 2008 financial results 13Health News:NUVO announces third quarter 2008 financial results 14Health News:NUVO announces third quarter 2008 financial results 15
... The Vibratome 1500 Sectioning System provides a ... animal, or plant tissues. The 1500 ... sectioning without freezing or embedding. The ... the destruction of enzyme activities, and other ...
... The original Vibratome Semi-Automatic Tissue Sectioning ... rock solid tissue sectioning system. Researchers from ... Vibratome 1000 Classic for their fresh and ... 20 years. With the Vibratome ...
... Vibratome 3000 Plus Sectioning System provides a ... animal, or plant tissues. The 3000 ... sectioning without freezing or embedding. The ... the destruction of enzyme activities, and other ...
... Sectioning System provides a versatile means of ... tissues. The 1500 employs a vibrating ... or embedding. The creation of artifacts, ... enzyme activities, and other deleterious effect inherent ...
Medicine Products: